射血分数改善的心衰患者停用指南导向药物治疗的预后研究
本研究基于瑞典心衰注册数据,纳入8728例射血分数改善(EF从<40%升至≥40%)的心衰患者,评估停用RASi/ARNi、BBL和MRA的比例及与1年心血管死亡/心衰住院的关联。结果显示停药率分别为4.4%、3.3%和17.2%,停用RASi/ARNi和MRA与风险升高38%和36%相关,停用BBL无整体关联但存在EF改善程度异质性。
要点
- EF改善的心衰患者中停用RASi/ARNi和MRA与1年心血管死亡/心衰住院风险升高相关。
- 停用BBL整体无显著关联,但EF改善至40-49%亚组风险升高,≥50%亚组无此关联。
- 研究提示需随机对照试验验证EF改善后BBL停用的安全性。
核心结论
- 在射血分数改善的心衰患者中,停用RASi/ARNi和MRA与1年心血管死亡/心衰住院风险升高独立相关,停用BBL无整体关联但存在EF改善程度异质性。
主要发现
- EF<40%时RASi/ARNi、BBL、MRA使用率分别为96%、94%、46%,EF改善时停药率分别为4.4%、3.3%、17.2%。
- 停药预测因素包括其他心衰药物使用较少、 later EF登记时EF较高、两次EF评估间隔较长。
- 加权后停用RASi/ARNi与主要终点风险升高38%相关,停用MRA升高36%,停用BBL无显著关联。
- 停用BBL在EF改善至40%-49%亚组中与主要终点风险升高相关(P-interaction 0.03)。
关键数值与推荐
- 停药定义为首次(EF降低)登记时用药而第二次(EF改善)登记时未用药。
- 主要终点为心血管死亡/心衰住院,采用Cox回归模型及重叠权重法,删失于1年。
临床怎么用
- 对EF改善的心衰患者,应继续RASi/ARNi和MRA治疗以降低1年心血管死亡/心衰住院风险。
- BBL停用需谨慎,尤其EF改善至40%-49%的患者,继续BBL可能获益。
局限性
- 回顾性观察性研究,结果仅为假设生成,需随机对照试验验证BBL停用的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited evidence exists on the prognostic role of continuing medical therapy in patients with heart failure (HF) and an ejection fraction (EF) that has improved over time. This study assessed rates of, patient profiles, and associations with morbidity/mortality of renin-angiotensin inhibitors (RASi), angiotensin receptor-neprilysin inhibitors (ARNi), beta-blockers (BBL), and mineralocorticoid receptor antagonists (MRA) withdrawal in patients with HF with improved EF. METHODS: Patients with a first recorded EF <40% and a later EF ≥40% from the Swedish HF registry between June 11, 2000, and December 31, 2023, were included in this retrospective observational study. Withdrawal was defined as a patient on treatment at the first (reduced) but not at the second (improved) registration. The association between withdrawal and time to first cardiovascular mortality/hospitalization for HF with censoring at 1 year was assessed by Cox regression model using overlap weighting. RESULTS: Of 8728 patients with HF with improved EF (median age, 70 years [25th to 75th percentile, 61-78], 2611 [29.9%] women), 96%, 94%, and 46% received RASi/ARNi, BBL, and MRA, respectively, when EF was <40%. The withdrawal rates at the time of the improved EF registration were 4.4% for RASi/ARNi, 3.3% for BBL, and 17.2% for MRA. Predictors of withdrawal included lower use of other HF medications, higher EF at the later EF registration, and a longer time between the 2 EF assessments. After weighting, withdrawal was independently associated with a higher risk of cardiovascular mortality/hospitalization for HF by 38% for RASi/ARNi and 36% for MRA, but not for BBL. Withdrawal of BBL was associated with a higher risk of the primary outcome in the subgroup of patients with an improved EF of 40% to 49% versus ≥50% (P-interaction 0.03). CONCLUSIONS: In patients with HF with improved EF, HF therapy withdrawal was rare. Withdrawing RASi/ARNi and MRA was associated with higher mortality/morbidity at 1 year. No association was found for BBL withdrawal, albeit with a significant heterogeneity for EF at improvement, suggesting better outcomes with continuing BBL only until EF improves up to 50%. These results are hypothesis-generating and highlight the need for randomized controlled trials testing BBL withdrawal in patients with HF with improved EF.
引用
- Basile, Lindberg, Benson, et al. Withdrawal of Guideline-Directed Medical Therapy in Patients With Heart Failure and Improved Ejection Fraction. Circulation. 2025. PMID: 40091747. doi:10.1161/CIRCULATIONAHA.124.072855
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。